✓ Translated by DotMD AI Clinical Council Source: Dermatitis : contact, atopic, occupational, drug • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40152029 ↗

Phase III Randomized Trial: Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis

Original Paper Title: “Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The patient-reported outcomes also improved sustainedly. Conclusions: Long-term stapokibart treatment induced sustained clinical improvements in adult patients with moderate-to-severe AD, regardless of their initial response to 16-week treatments.
  • Study Design & Sample: Phase III Randomized Trial published in Dermatitis : contact, atopic, occupational, drug (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Dermatitis : contact, atopic, occupational, drug (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Background: Stapokibart has been approved for the treatment of adults with atopic dermatitis (AD) in China. Key clinical takeaway: The patient-reported outcomes also improved sustainedly. Conclusions: Long-term stapokibart treatment induced sustained clinical improvements in adult patients with moderate-to-severe AD, regardless of their initial response to 16-week treatments.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Dermatitis : contact, atopic, occupational, drug, 2026-01-15; Phase III Randomized Trial; Rigor 88/100): The patient-reported outcomes also improved sustainedly. Conclusions: Long-term stapokibart treatment induced sustained clinical improvements in adult patients with moderate-to-severe AD, regardless of their initial response to 16-week treatments.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: pityriasis-capitis → Condition: skin-condition-hypertrophic →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40152029: Phase III Randomized Trial: Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis

3 of 3 Free Questions Remaining